Navilyst executive becomes AngioDynamics CTO.
Bourne served as senior vice president of research and development (R&D) and clinical affairs for Navilyst Medical, a medical device manufacturer focused in the vascular access sector, from its formation in early 2008 until November 2011. His tenure was defined by focused portfolio development and the commercialization of new products. Most recently, he served as vice president of R&D at Hologic Inc. Previously, he spent 10 years at Boston Scientific Corp. as vice president of R&D of the urology, medtech and oncology business units and then as group vice president of R&D for the endosurgery business group. He also served in leadership positions at Baxter Healthcare, Allegiance Healthcare and C.R. Bard Inc. Bourne earned his B.S. in biological science and a master's of science in plastics engineering from the University of Lowell in Lowell, Mass., He also received an M.B.A. from Rivier College in Nashua, N.H.
"George is a world-class engineer whose commitment to operational excellence has led him to establish and manage high-performance medical device R&D organizations," said Joseph M. DeVivo, CEO of AngioDynamics. "His extensive knowledge of Navilyst Medical's technology, pipeline and organization, combined with 25 years of experience in developing products in global medical device companies, make George the ideal fit for this important executive role."
Bourne said in a prepared statement: "The combination of AngioDynamics and Navilyst will create a more comprehensive and competitive portfolio of products differentiated by advanced technologies. I look forward to working with Joseph DeVivo and his team to expand our product offering and drive growth."
AngioDynamics' acquisition of Navilyst Medical is expected to expand the company's reach, doubling its share of the vascular access market, while "building critical mass" in the peripheral vascular market, according to company executives. Under the terms of the agreement, AngioDynamics will acquire Navilyst Medical from Avista Capital Partners, a private equity firm, for $373.7 million in cash and stock.
Founded in 1988, AngioDynamics provides minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||PEople News|
|Publication:||Medical Product Outsourcing|
|Date:||Jun 1, 2012|
|Previous Article:||Covidien elects new treasurer.|
|Next Article:||Oakworks appoints new director of business development.|